Archer (ASX:AXE) share price retreats despite positive update

The Archer Materials Ltd (ASX: AXE) share price has retreated in late-afternoon despite announcing a positive update. Here's the details.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Archer Materials Ltd (ASX: AXE) share price has retreated in late-afternoon trade after soaring as high as 93.5 cents. This comes after the company announced that it has begun to progress on the pathway for sub-10 nanometre biochip fabrication.

At the time of writing, the advanced material company's shares are fetching 90 cents apiece, flat for the day.

4DS share price

Image source: Getty Images

Development plans

Archer shares were trading on a high earlier on but have since fallen back to yesterday's market close.

According to its release, Archer advised it has commenced development to produce biochip components that are under 10 nanometres (nm) in size. In comparison, a human hair is around 75 microns or 75,000 nm.

Archer noted that miniaturisation to below 10 nm is a key requirement for the operation and end-use of its biochip. Anything less than 10nm is considered as best-in-class across the semiconductor industry.

The company explained that if successful in creating prototype biochip devices, it would remove significant barriers to entry. This includes pattern design and process optimisation, for on-chip fabrication of biosensor components.

What did the CEO say?

Archer CEO, Dr Mohammad Choucair touched on the company's nanofabrication development, saying:

Archer has progressed to one of the most advanced forms of nanofabrication after recently translating biosensor components onto silicon wafers. We are expanding on this strength with in-house capability to build a robust biochip IP portfolio. This is key to Archer's long-term growth, and near-term speed of execution in its deep tech development.

Best-in-class capabilities in nanofabrication is a global competitive advantage in the multibillion-dollar point of care medical diagnostics industry. One of the reasons why there are few companies in the world developing and commercialising biochips is because it's difficult to achieve precision engineering at the nano scale.

Archer share price summary

Over the past year, the Archer share price has accelerated over 400%, with 75% of those gains coming in 2021 so far. The company's shares reached an all-time high of $1.24 in late February on the back of achieving a technological breakthrough.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on Westpac and CBA shares

A leading expert forecasts growing headwinds for Westpac and CBA shares.

Read more »

Man looking at digital holograms of graphs, charts, and data.
Broker Notes

Expert names 2 ASX tech shares to buy today

A top analyst says these two ASX tech stocks are well-positioned to outperform.

Read more »

An old-fashioned panel of judges each holding a card with the number 10
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the week for investors this Friday.

Read more »

Woman thinking in a supermarket.
Dividend Investing

Coles stock vs Woolworths shares: Who had the better dividend this week?

Let's check the receipts on Coles and Woolies this week.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Broker Notes

4 ASX All Ords shares with 40% to 90% upside post-results: experts

These shares have major upside potential, according to the experts.

Read more »

Woman looking at a laptop and thinking.
Broker Notes

4 ASX shares scoring upgrades in the final week of earnings season

Brokers have increased their ratings on Sigma Healthcare, Adairs, Netwealth, and other shares.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Buy, hold, sell: Netwealth, Sigma Healthcare, and Wesfarmers shares

The team at Morgans has given its verdict on these shares.

Read more »

Smiling kid flexing his muscles.
Broker Notes

3 ASX 200 shares to buy post-results: broker

Morgans has reviewed these companies' FY26 reports and given them a buy rating.

Read more »